



Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

March 15, 2018

CINCINNATI--(BUSINESS WIRE)--Mar. 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that President and Founder, Joseph Gardner, Ph.D., will present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00 a.m. Eastern Time in New York, N.Y. Dr. Gardner will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information please visit www.aerpio.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180315005395/en/>

Source: Aerpio Pharmaceuticals, Inc.

Investor & Media:

Aerpio Pharmaceuticals, Inc.

Michael Rogers, 513-985-1958

Chief Financial Officer

or

Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.

Media:

Justin Jackson

jjackson@burnsmc.com

or

Investors:

Ami Bavishi

abavishi@burnsmc.com